Accurate diagnosis of mesothelioma: More important than ever

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 5, 2013, Pages 601-602

  Allen, Timothy Craig ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; EDITORIAL; HUMAN; LUNG TUMOR; MESOTHELIOMA; PLEURA TUMOR;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 84877980080     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0260-ED     Document Type: Editorial

References (24)

1. Al-Taei S, Salimu J, Lester JF, et al. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma [published online ahead of print April 10, 2012]. Lung Cancer. doi: http://dx.doi.org/10.1016/j.lungcan.2012.03.008.
2. Yamashita T, Nagano K, Kanasaki SI, et al. Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells [published online ahead of print April 4, 2012]. Biochem Biophys Res Commun. 2012; 421(1):140-144. doi: http://dx.doi.org/10.1016/j.bbrc.2012.03.144.
3. Pasello G, Ceresoli GL, Favaretto A. An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma [published online ahead of print March 27, 2012]. Cancer Treat Rev. doi: 10. 1016/j.ctrv.2012.03.001.
4. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(4):737-743.
5. Bille A, Belcher E, Raubenheimer H, et al. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals. Gen Thorac Cardiovasc Surg. 2012;60(5):289-296.
6. Suzuki H, Hirashima T, Kobayashi M, et al. Prognostic factors in malignant pleural mesothelioma: a retrospective study. Intern Med. 2012;51(7):707-710.
7. Grosso F, Scagliotti GV. Systemic treatment of malignant pleural mesothelioma. Future Oncol. 2012;8(3):293-305.
8. Takanen S, Resuli B, Graziano V, et al. Complete response and long-term survival in malignant pleural mesothelioma: case report. Anticancer Res. 2012; 32(4):1485-1487.
9. Myojin T, Azuma K, Okumura J, Uchiyama I. Future trends of mesothelioma mortality in Japan based on a risk function [published online ahead of print March 28, 2012]. Ind Health. http://dx.doi.org/10.2486/indhealth. MS1184.
10. Matsuzaki H, Maeda M, Lee S, et al. Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis. J Biomed Biotechnol. 2012;2012: 492608. doi:10.1155/2012/492608.
11. Bahnassy AA, Zekri AR, El-Deftar MM, et al. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients [published online ahead of print April 6, 2012]. Exp Mol Pathol. 2012;93(1):154-161.
12. Tabata C, Terada T, Tabata R, et al. Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma [published online ahead of print March 28, 2012]. J Clin Gastroenterol. doi: 10.1097/MCG.0b013e31824e901b.
13. Cedres S, Montero MA, Martinez P, et al. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM) [published online ahead of print March 27, 2012]. Lung Cancer. http://dx.doi.org/10.1016/j.lungcan.2012.02.022.
14. Enomoto Y, Kasai T, Takeda M, et al. A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol Int. 2012;62(4):226-231.
15. Kalra N, Ashai A, Xi L, et al. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. Oncol Rep. 2012;27(6):1794-1800.
16. Okada A, Yaguchi T, Kanno T, Gotoh A, Nakano T, Nishizaki T. PDGF-D/PDGF-bb receptor-regulated chemotaxis of malignant mesothelioma cells. Cell Physiol Biochem. 2012;29(1-2):241-250.
17. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis [published online ahead of print March 12, 2012]. J Clin Oncol. 2012;30(13): 1541-1549. doi: 10.1200/JCO.2011.39.6671.
18. Enomoto Y, Kasai T, Takeda M, et al. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma [published online ahead of print March 12, 2012]. J Clin Pathol. 2012;65(6):522-527. doi:10.1136/jclinpath-2011-200631.
19. Haas AR, Sterman DH. Novel intrapleural therapies for malignant diseases. Respiration. 2012;83(4):277-292.
20. Izzi V, Masuelli L, Tresoldi I, Foti C, Modesti A, Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune-response-based therapies [published online ahead of print April 23, 2012]. Cancer Lett. 2012;322(1):18-34. doi: 10.1016/j.canlet.2012.02.034.
21. Neri M, Ugolini D, Boccia S, et al. Chemoprevention of asbestos-linked cancers: a systematic review. Anticancer Res. 2012;32(3):1005-1013.
22. Cao C, Yan TD, Morris DL, et al. Prospective registry on mesothelioma peritonei treatment (PROMPT): study design and rationale. Tumori. 2012;98(1): 166-171.
23. Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2012;137(5): 647-667.
24. Husain AN, Colby TV, Ord́o?nez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133(8): 1317-1331.